Characteristics of clinically significant inhibitors
| Characteristic . | All inhibitors (n = 114) . | High-titer inhibitors* (n = 63) . | Low-titer inhibitors (n = 51) . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | % . | M . | IQR . | No. . | % . | M . | IQR . | No. . | % . | M . | IQR . | |
| No. of EDs at inhibitor detection | 13 | 8-19 | 11 | 7-16 | 17 | 8-22 | ||||||
| Age at inhibitor detection, mo | 15.2 | 11.1-22.8 | 12.8 | 8.7-18.8 | 18.6 | 14.8-30.3 | ||||||
| Duration between first ED and inhibitor detection, mo | 4.3 | 2.0-9.6 | 3.0 | 1.5-6.7 | 7.3 | 2.8-18.2 | ||||||
| Maximal inhibitor titer, BU/mL | 7.5 | 2.1-69.0 | 53.0 | 13.0-220.0 | 2.0 | 1.0-3.2 | ||||||
| Treatments received at any time during FranceCoag follow-up | ||||||||||||
| Bypassing agents | 77 | 67.5 | 55 | 87.3 | 22 | 43.1 | ||||||
| ITI | 79 | 69.3 | 52 | 82.5 | 27 | 52.9 | ||||||
| Bypassing agents and/or ITI | 95 | 83.3 | 59 | 93.7 | 36 | 70.6 | ||||||
| Characteristic . | All inhibitors (n = 114) . | High-titer inhibitors* (n = 63) . | Low-titer inhibitors (n = 51) . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | % . | M . | IQR . | No. . | % . | M . | IQR . | No. . | % . | M . | IQR . | |
| No. of EDs at inhibitor detection | 13 | 8-19 | 11 | 7-16 | 17 | 8-22 | ||||||
| Age at inhibitor detection, mo | 15.2 | 11.1-22.8 | 12.8 | 8.7-18.8 | 18.6 | 14.8-30.3 | ||||||
| Duration between first ED and inhibitor detection, mo | 4.3 | 2.0-9.6 | 3.0 | 1.5-6.7 | 7.3 | 2.8-18.2 | ||||||
| Maximal inhibitor titer, BU/mL | 7.5 | 2.1-69.0 | 53.0 | 13.0-220.0 | 2.0 | 1.0-3.2 | ||||||
| Treatments received at any time during FranceCoag follow-up | ||||||||||||
| Bypassing agents | 77 | 67.5 | 55 | 87.3 | 22 | 43.1 | ||||||
| ITI | 79 | 69.3 | 52 | 82.5 | 27 | 52.9 | ||||||
| Bypassing agents and/or ITI | 95 | 83.3 | 59 | 93.7 | 36 | 70.6 | ||||||
High-titer inhibitor defined as peak titer ≥5 BU/mL at any time during FranceCoag follow-up.